Total antioxidant capacity and total oxidant status in patients with major depression: Impact of antidepressant treatment

Basit Öğe Kaydı
dc.authoridKarlıdağ, Rifat/0000-0002-3650-0774
dc.authoridOZYURT, Huseyin/0000-0003-2327-4082
dc.authorwosidKarlıdağ, Rifat/AAB-4281-2021
dc.authorwosidkarlıdağ, rıfat/AAB-4255-2021
dc.authorwosidOZYURT, Huseyin/N-4351-2015
dc.contributor.authorCumurcu, Birgul Elbozan
dc.contributor.authorOzyurt, Huseyin
dc.contributor.authorEtikan, Ilker
dc.contributor.authorDemir, Suleyman
dc.contributor.authorKarlidag, Rifat
dc.date.accessioned2024-08-04T20:31:19Z
dc.date.available2024-08-04T20:31:19Z
dc.date.issued2009
dc.departmentİnönü Üniversitesien_US
dc.description.abstractAim: The purpose of the present study was to investigate whether total antioxidant capacity (TAC) and total oxidant status (TOS) are associated with major depressive disorder (MDD) and to evaluate the impact of antidepressant treatment on TAC and TOS in MDD. Methods: Fifty-seven MDD patients and 40 healthy controls participated in the study. Serum TAC and TOS were measured both in patients and controls using Erel's methods. Patients were treated with antidepressant drugs for 12 weeks. The treatment course was evaluated using the Montgomery-Asberg Depression Rating Scale (MADRS) in all patients. Results: TOS and oxidative stress index (OSI) were higher (P = 0.0001 for both) and TAC was lower (P = 0.0001) in the MDD group compared with those of the controls. After 3 months of antidepressant treatment, TOS and OSI were decreased and TAC was increased compared with the pretreatment values (P = 0.0001, for all). Furthermore, there were significant positive correlations between the severity of the disease and serum TOS and OSI (r = 0.584, P = 0.0001; r = 0.636, P = 0.0001, respectively). A negative correlation was found between the severity of the disease and serum TAC (r = -0.553, P = 0.0001) at the pre-treatment stage. Conclusion: Treatment administered for 3 months to MDD patients increases TAC while decreasing TOS and OSI.en_US
dc.identifier.doi10.1111/j.1440-1819.2009.02004.x
dc.identifier.endpage645en_US
dc.identifier.issn1323-1316
dc.identifier.issn1440-1819
dc.identifier.issue5en_US
dc.identifier.pmid19674383en_US
dc.identifier.scopus2-s2.0-70349303534en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage639en_US
dc.identifier.urihttps://doi.org/10.1111/j.1440-1819.2009.02004.x
dc.identifier.urihttps://hdl.handle.net/11616/94878
dc.identifier.volume63en_US
dc.identifier.wosWOS:000270153200005en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofPsychiatry and Clinical Neurosciencesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectantidepressant treatmenten_US
dc.subjectmajor depressive disorderen_US
dc.subjecttotal antioxidant capacityen_US
dc.subjecttotal oxidant statusen_US
dc.titleTotal antioxidant capacity and total oxidant status in patients with major depression: Impact of antidepressant treatmenten_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu